Advertisement
Advertisement
U.S. markets open in 8 hours 44 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Fate Therapeutics, Inc. (FATE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
24.22+2.41 (+11.05%)
At close: 04:00PM EDT
24.10 -0.12 (-0.50%)
After hours: 07:44PM EDT
Advertisement

Fate Therapeutics, Inc.

12278 Scripps Summit Drive
San Diego, CA 92131
United States
858 875 1800
https://www.fatetherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees449

Key Executives

NameTitlePayExercisedYear Born
Mr. J. Scott WolchkoFounder, CEO, Pres & Director976k25.12M1970
Mr. Edward J. Dulac IIIChief Financial Officer588k821.37k1976
Dr. Mark Plavsic D.V.M., Ph.D.Chief Technical Officer634.51kN/A1961
Ms. Cindy R. TahlGen. Counsel & Corp. Sec.602k13.37M1973
Dr. Bahram Valamehr Ph.D.Chief R&D Officer602k7.11M1977
Dr. Yu-Waye Chu M.D.Chief Medical Officer602k263.51kN/A
Mr. Jim Beitel M.B.A.Sr. VP of Corp. Devel.N/AN/AN/A
Dr. Sarah CooleySr. VP of Clinical TranslationN/AN/AN/A
Dr. Jerome Bressi Ph.D.Sr. VP of Regulatory Affairs & Quality AssuranceN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Corporate Governance

Fate Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement